Histogen Net Worth
Histogen Net Worth Breakdown | HSTO |
Histogen Net Worth Analysis
Histogen's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Histogen's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Histogen's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Histogen's net worth analysis. One common approach is to calculate Histogen's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Histogen's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Histogen's net worth. This approach calculates the present value of Histogen's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Histogen's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Histogen's net worth. This involves comparing Histogen's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Histogen's net worth relative to its peers.
Enterprise Value |
|
To determine if Histogen is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Histogen's net worth research are outlined below:
| Histogen generated a negative expected return over the last 90 days | |
| Histogen has high historical volatility and very poor performance | |
| Histogen has some characteristics of a very speculative penny stock | |
| Histogen has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 19 K. Net Loss for the year was (12.38 M) with loss before overhead, payroll, taxes, and interest of (1.25 M). | |
| Histogen currently holds about 12.6 M in cash with (10.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Histogen has a frail financial position based on the latest SEC disclosures |
Histogen uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Histogen. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Histogen's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 9th of November 2023 Upcoming Quarterly Report | View | |
| 30th of September 2023 Next Fiscal Quarter End | View | |
| 30th of June 2023 Last Quarter Report | View |
Know Histogen's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Histogen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Histogen backward and forwards among themselves. Histogen's institutional investor refers to the entity that pools money to purchase Histogen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Highlander Capital Management Llc | 2024-03-31 | 17.0 |
Follow Histogen's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 85.44 K.Market Cap |
|
Project Histogen's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.64) | (0.67) | |
| Return On Capital Employed | (0.69) | (0.72) | |
| Return On Assets | (0.64) | (0.67) | |
| Return On Equity | (0.85) | (0.89) |
When accessing Histogen's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Histogen's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Histogen's profitability and make more informed investment decisions.
Evaluate Histogen's management efficiency
Histogen has return on total asset (ROA) of (0.5381) % which means that it has lost $0.5381 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1989) %, meaning that it created substantial loss on money invested by shareholders. Histogen's management efficiency ratios could be used to measure how well Histogen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of December 2024, Return On Tangible Assets is likely to drop to -0.67. In addition to that, Return On Capital Employed is likely to drop to -0.72. At this time, Histogen's Total Assets are very stable compared to the past year. As of the 1st of December 2024, Non Current Assets Total is likely to grow to about 6.8 M, while Total Current Assets are likely to drop about 11.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.79 | 4.55 | |
| Tangible Book Value Per Share | 4.79 | 4.55 | |
| Enterprise Value Over EBITDA | 0.41 | 0.43 | |
| Price Book Value Ratio | 0.21 | 0.20 | |
| Enterprise Value Multiple | 0.41 | 0.43 | |
| Price Fair Value | 0.21 | 0.20 | |
| Enterprise Value | -5.5 M | -5.3 M |
Understanding the operational decisions made by Histogen management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 2.8893 | Revenue 19 K | Revenue Per Share 0.004 | Return On Equity (1.20) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Histogen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Histogen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Histogen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Spada Alfred P over a year ago Acquisition by Spada Alfred P of 313436 shares of Histogen subject to Rule 16b-3 | ||
Satz Brian over a year ago Acquisition by Satz Brian of 6835 shares of Histogen subject to Rule 16b-3 | ||
Spada Alfred P over a year ago Acquisition by Spada Alfred P of 106793 shares of Histogen subject to Rule 16b-3 | ||
Spada Alfred P over a year ago Histogen exotic insider transaction detected |
Histogen Earnings per Share Projection vs Actual
Histogen Corporate Management
| Stephen Hill | VP Controller | Profile | |
| Steven Mento | Interim Chairman | Profile | |
| Thomas Hubka | Director Sec | Profile | |
| Gail Naughton | Founder Advisor | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Histogen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Histogen Stock, please use our How to Invest in Histogen guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Histogen. If investors know Histogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Histogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.81) | Revenue Per Share 0.004 | Return On Assets (0.54) | Return On Equity (1.20) |
The market value of Histogen is measured differently than its book value, which is the value of Histogen that is recorded on the company's balance sheet. Investors also form their own opinion of Histogen's value that differs from its market value or its book value, called intrinsic value, which is Histogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Histogen's market value can be influenced by many factors that don't directly affect Histogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Histogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Histogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Histogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.